12 results about "Cyclophilin" patented technology

The application provides a nanobody targeting human transmembrane activator and calcium modulator and cyclophilin interactor (TACI) and an application thereof, and the antibody is derived from a llama heavy chain antibody variable region. The anti-TACI single-domain antibody NB38 can specifically bind to human TACI with high affinity, can recognize a recombinant TACI protein, can also recognize a TACI with a natural conformation on a cell surface, and can partially block a BAFF / APRIL signal pathway. Based on the nanobody, the application constructs a fusion protein, a chimeric antigen receptor, an effector cell expressing the chimeric antigen receptor, and a double-specific cell linker and other genetically engineered forms. The nanobody can be further extended into a drug coupling form. The product of the application can be used for mediating directional recognition and killing of TACI positive cells, and can be used as a supplement and expansion of BCMA targeted therapy, and provides a new candidate technical scheme for targeted therapy of multiple myeloma and other TACI related diseases.

The present invention concerns the use of peptidyl-prolyl isomerase cyclophilin 40 (CyP40) for reduction of neurotoxic fibrils and treatment and prevention of neurodegenerative diseases associated with amyloid fibril aggregation. Aspects of the invention include compositions, methods, dosage forms, and kits for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation in a human or animal subject, and for disaggregating neurofibrillary aggregates in vitro or in vivo, using CyP40, or a biologically active fragment thereof.

The present disclosure provides compounds defined by Formulae 1-6 and their use as cyclophilin inhibitors for the prevention or treatment of a disease or disorder, such as a cyclophilin-mediated disease or disorder, in particular a cyclophilin A-mediated disease or disorder.

Compounds defined by Formula 4 are used as cyclophilin inhibitors for the prevention or treatment of diseases or disorders, in particular diseases or conditions associated with cellular injury or cell death, such as organ injury or organ failure, which can be caused by a number of different reasons, such as ischemia or ischemia reperfusion injury, toxins, infection or mechanical trauma.

The application discloses a neutralizing nucleic acid aptamer capable of specifically combining with human APRIL and application thereof in inhibiting antibody secretion. The neutralizing nucleic acid aptamer of the application can efficiently neutralize extracellular APRIL molecules in vitro and in vivo, thereby blocking the combination of the molecules with a human calcium-binding cyclophilin ligand-interacting molecule (TACI) and a B cell maturation antigen (BCMA) on a B cell membrane, and finally inhibiting the generation and secretion of antibodies. Compared with the existing biological preparation atacicept for targeting and neutralizing APRIL, the APRIL neutralizing nucleic acid aptamer involved in the application has the advantages of high specificity, high affinity, low immunogenicity and low cost, is a novel nucleic acid drug preparation for inhibiting antibody secretion, and has a great clinical application prospect.

The invention provides antibodies, antibody-drug conjugates, bispecific T cell engagers (BiTEs), and chimeric antigen receptors (CARs) that target transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). Such antibodies, antibody-drug conjugates, BiTEs, and CARs can be used, e.g., in methods for treating a cancer (e.g., multiple myeloma), an autoimmune disorder (e.g., characterized by a high titer of antibodies contributing to the disorder), or a plasma cell disease disorder (e.g., plasma cell dyscrasias) in a subject in need thereof.

This invention discloses a neutralizing nucleic acid aptamer that targets and inhibits B-cell activating factors and its application in the treatment of systemic lupus erythematosus (SLE). The neutralizing nucleic acid aptamer described in this invention can efficiently inhibit the binding of BAFF to specific receptors on the B-cell membrane, including the BAFF receptor (BAFF-R), human calmotropic cyclin ligand-interacting molecule (TACI), and B-cell maturation antigen (BCMA), thereby reducing the proportion of plasma cells, plasmablasts, and germinal center B cells, ultimately reducing the production and secretion of autoantibodies, thus exhibiting a targeted therapeutic effect on SLE. Compared with existing BAFF-neutralizing biological agents, the neutralizing nucleic acid aptamer of this invention has advantages such as high specificity, high affinity, ease of synthesis, low immunogenicity, low cost, and designability and programmability, making it a potential novel nucleic acid agent for targeted SLE therapy with excellent prospects for clinical translational applications.

The present invention provides compounds for use in selectively modulating cyclophilin mediated processes in general. In particular, the invention provides compounds for use in treating diseases such as hyper-proliferative disorders, immunity and inflammation disorders and metabolic dysfunction associated steatohepatitis. Additionally or alternatively, the present invention particularly provides compounds for use in engaging an organism's immune system to target a specific cell, specific cells, a cell-type, an organelle or an organ in that organism.

The present invention relates to stilbene derivatives and a method for preparing the same. More particularly, the present invention relates to novel stilbene derivatives which inhibit the function of cyclophilins and are effective in preventing cyclophilin-related diseases or treating symptoms thereof, and a method for preparing the same.

This invention discloses a Cyclophilin antibacterial protein gene from the Minjiang lily. LrCYP1 Its nucleotide sequence is as described in SEQ ID NO: 1, encoding a protein with the amino acid sequence shown in SEQ ID NO: 2. This invention confirms through functional genomics-related research. LrCYP1 The gene has the function of enhancing plant antifungal resistance, and the antifungal properties of this invention... LrCYP1 Genes were constructed into plant expression vectors and overexpressed in tobacco. The transgenic tobacco plants exhibited strong resistance to fungal infection, demonstrating the effectiveness of overexpression. LrCYP1 The genetically modified tobacco plants exhibit high levels of resistance to Alternaria alternata and Pseudomonas spp.

Provided herein is an antigen-binding protein that specifically binds and / or detects the transmembrane activator and calcium-modulator and cyclophilin ligand (CAML) interactor (TACI) / TNFRSF13B, wherein the antigen binding protein comprises a CDR sequence having GFSITSDYA (SEQ ID NO: 1) for CDRH1, ISYSGST (SEQ ID NO: 2) for CDRH2, ARVVSTSFDS (SEQ ID NO: 3) for CDRH3, ESVDNYGISF (SEQ ID NO: 4) for CDRL1, VAS (SEQ ID NO: 5) for CDRL2, and QQSKEVPYT (SEQ ID NO: 6) for CDRL3, or having amino acid sequences that are at least 85% identical to the sequences, or sequences having 1 or 2 amino acids different from the sequences thereof. Also provided herein are polynucleotides, vectors, and host cells thereof. Further provided herein arc pharmaceutical compositions and methods of treating a discasc, such as TACI-positive multiple mycloma.

Compounds as defined by Formulas 1-3 and uses thereof for as cyclophilin inhibitors, for the prevention or treatment of diseases or conditions such as cyclophilin-mediated diseases or conditions, in particular, cyclophilin A or cyclophilin D-mediated diseases or conditions.